Last reviewed · How we verify

Collaborative Neuroscience Research, LLC — Portfolio Competitive Intelligence Brief

Collaborative Neuroscience Research, LLC pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Xanomeline and Trospium Chloride Xanomeline and Trospium Chloride marketed Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism) Psychiatry / Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Collaborative Neuroscience Research, LLC:

Cite this brief

Drug Landscape (2026). Collaborative Neuroscience Research, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/collaborative-neuroscience-research-llc. Accessed 2026-05-17.

Related